Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin versus placebo for counterregulatory response during insulin-induced hypoglycemia in type 2 diabetes
2016-003126-16Phase 2Terminated
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of canagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Azienda Ospedaliero-Universitaria Pisana. Primary endpoint: Change in plasma glucagon concentration. Started Jun 2021; status: terminated.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-003126-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003126-16.